Innoxel Lifesciences received a USFDA EIR, clearing its Vadodara facility for the commercial supply of liquid and oral injectables.

• USFDA inspection was completed between April 28 and May 2, 2025, with full compliance confirmed.
• Facility approved for manufacturing, packaging, and distribution of complex dosage forms like liquid injectables and oral liquids.
• This milestone boosts Innoxel's global credibility and opens doors to US and EU-regulated pharmaceutical markets.